Columns | View from Brussels

Find out what the new EU framework entails; a think tank finds that too much health care energy is going into medicine.

Even as the EU implementation deadline looms, clear clinical trial definitions remain elusive.

European Research Commissioner Philippe Busquin tours Africa to bring attention to the plight of developing nations unable to afford modern medicines.

The issue of prioritizing clinical trials of pediatric medicines continues to simmer, as plans for planning the possible future legislation develop.

Pediatrics and geriatrics are the latest hot topics in the EU, so the CPMP is at least starting to help companies develop new clinical trials for children.

After committing itself to researching poverty-linked diseases, the EU is working to decide what responsibilities it has to EU-funded research activities in developing nations.

The latest wrinkle in the European Union?s clinical trials rules debate comes from modifications of the draft text at the core of its proposal.

European organizations express their concerns over the implications of the EU guidances issued in response to the 2001 directive.

The consumer press has its spotlight on clinical research again, and some commentators are focusing on subject recruitment.

With 2003 fast approaching, all we know for sure about the EU?s legislative changes is that nothing is final yet.

The World Summit on Sustainable Development may have fizzled, but a promising new long-term clinical trials partnership between the EU, industry, and developing countries is in the works.

Integrating IVRS with in-house clinical trial management solutions can provide a powerful project management tool.

The EU?s progress in the battle against cancer measures how effective it is as research supporter instead of regulatory enforcer.

A set of trials carried out by the Collaborative Ocular Melanoma Study Group at eye centers throughout the United States and Canada led to improvements in the care of patients with choroidal melanoma.

Many stakeholders have already commented on the EU?s incentives for pediatric drug development.

The European Union is working to develop pediatric rules to ensure that medicines prescribed for children are safe, effective, and of high quality.

At work and play, he?s devoted to children.

EU proposals are finally available for the pharmaceutical industry to begin commenting on, and you can bet the industry will take advantage of it.

A new guideline details basic requirements for submitting a successful application for a proposed orphan drug in the European Union.

Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.

With the impending expansion of the EU and the revamping of current policies, the pharmaceutical industry is on edge, wanting to know what the future holds.

To help protect patient safety and cut red tape, the European Union is working to create tougher standards of pharmacovigilance.

European Parliament debates on the allocation of research funds reveals Euro-MPs views of clinical research in medicines development.

A high-level group explores ways to support EU pharmaceutical industry research without too much cost to the EU health agencies that pay for medicines.

The EU?s Committee for Proprietary Medicinal Products describes the process clinical investigations should follow.

Patients, research companies, and regulatory authorities may all benefit from proposed changes to current pharmaceutical legislation, but the proposals will provoke much debate.

The EMEA updates its positions on placebos, Crohn?s disease trials, and postmarketing surveillance of drugs used by pregnant women.